Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway

British Journal of Cancer

Volumn 110, Issue 4, 2014, Pages 946-957

  Zhang, B ^a,b,c   Chen, X ^d   Bae, S ^b   Singh, K ^b   Washington, M K ^e   Datta, P K ^a,b,c  

^a BIRMINGHAM VA MEDICAL CENTER   (United States)

^b University of Alabama at Birmingham   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CHROMONES; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; ENZYME INHIBITORS; FLUOROURACIL; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICE; MICE, INBRED BALB C; MORPHOLINES; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; REPRESSOR PROTEINS; RETINOBLASTOMA PROTEIN; SMAD4 PROTEIN; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84894340142     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.789     Document Type: Article

References (40)

1. Ahn BK, Jang SH, Paik SS, Lee KH (2011) Smad4 may help to identify a subset of colorectal cancer patients with early recurrence after curative therapy. Hepatogastroenterology 58(112): 1933-1936.
2. Alazzouzi H, Alhopuro P, Salovaara R, Sammalkorpi H, Jarvinen H, Mecklin JP, Hemminki A, Schwartz Jr. S, Aaltonen LA, Arango D (2005) SMAD4 as a prognostic marker in colorectal cancer. Clin Cancer Res 11(7): 2606-2611.
3. Alhopuro P, Alazzouzi H, Sammalkorpi H, Davalos V, Salovaara R, Hemminki A, Jarvinen H, Mecklin JP, Schwartz Jr. S, Aaltonen LA, Arango D (2005) SMAD4 levels and response to 5-fluorouracil in colorectal cancer. Clin Cancer Res 11(17): 6311-6316.
4. Azuma H, Ehata S, Miyazaki H, Watabe T, Maruyama O, Imamura T, Sakamoto T, Kiyama S, Kiyama Y, Ubai T, Inamoto T, Takahara S, Itoh Y, Otsuki Y, Katsuoka Y, Miyazono K, Horie S (2005) Effect of Smad7 expression on metastasis of mouse mammary carcinoma JygMC(A) cells. J Natl Cancer Inst 97(23): 1734-1746.
5. Baraniskin A, Munding J, Schulmann K, Meier D, Porschen R, Arkenau HT, Graeven U, Schmiegel W, Tannapfel A, Reinacher-Schick A (2011) Prognostic value of reduced SMAD4 expression in patients with metastatic colorectal cancer under oxaliplatin-containing chemotherapy: A translational study of the AIO colorectal study group. Clin Colorectal Cancer 10(1): 24-29.
6. Cancer Genome Atlas Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487(7407): 330-337.
7. Chen Q, Li W, Wan Y, Xia X, Wu Q, Chen Y, Lai Z, Yu C (2012) Amplified in breast cancer 1 enhances human cholangiocarcinoma growth and chemoresistance by simultaneous activation of Akt and Nrf2 pathways. Hepatology 55(6): 1820-1829.
8. Conery AR, Cao Y, Thompson EA, Townsend Jr. CM, Ko TC, Luo K (2004) Akt interacts directly with Smad3 to regulate the sensitivity to TGF-beta induced apoptosis. Nat Cell Biol 6(4): 366-372.
9. Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425(6958): 577-584.
10. Donigan M, Loh BD, Norcross LS, Li S, Williamson PR, DeJesus S, Ferrara A, Gallagher JT, Baker CH (2010) A metastatic colon cancer model using nonoperative transanal rectal injection. Surg Endosc 24(3): 642-647.
11. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355(9209): 1041-1047.
12. Fanciullino R, Giacometti S, Mercier C, Aubert C, Blanquicett C, Piccerelle P, Ciccolini J (2007) In vitro and in vivo reversal of resistance to 5-fluorouracil in colorectal cancer cells with a novel stealth double-liposomal formulation. Br J Cancer 97(7): 919-926.
13. Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3(5): 391-400.
14. Freeman TJ, Smith JJ, Chen X, Washington MK, Roland JT, Means AL, Eschrich SA, Yeatman TJ, Deane NG, Beauchamp RD (2012) Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of beta-catenin. Gastroenterology 142(3): 562-571 e562.
15. Galgano MT, Hampton GM, Frierson Jr. HF (2006) Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 19(6): 847-853.
16. Garofalo M, Quintavalle C, Zanca C, De Rienzo A, Romano G, Acunzo M, Puca L, Incoronato M, Croce CM, Condorelli G (2008) Akt regulates druginduced cell death through Bcl-w downregulation. PLoS One 3(12): E4070.
17. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18(1): 136-147.
18. Halder SK, Beauchamp RD, Datta PK (2005) A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia 7(5): 509-521.
19. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23): 2335-2342.
20. Ischenko I, Camaj P, Seeliger H, Kleespies A, Guba M, De Toni EN, Schwarz B, Graeb C, Eichhorn ME, Jauch KW, Bruns CJ (2008) Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: An involvement of epidermal growth factor receptor signaling. Oncogene 27(57): 7212-7222.
21. Jin W, Wu L, Liang K, Liu B, Lu Y, Fan Z (2003) Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells. Br J Cancer 89(1): 185-191.
22. Kang Y, He W, Tulley S, Gupta GP, Serganova I, Chen CR, Manova-Todorova K, Blasberg R, Gerald WL, Massague J (2005) Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA 102(39): 13909-13914.
23. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills GB, Mendelsohn J, Fan Z (2003) HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22(21): 3205-3212.
24. Kodach LL, Bos CL, Duran N, Peppelenbosch MP, Ferreira CV, Hardwick JC (2006) Violacein synergistically increases 5-fluorouracil cytotoxicity, induces apoptosis and inhibits Akt-mediated signal transduction in human colorectal cancer cells. Carcinogenesis 27(3): 508-516.
25. Losi L, Bouzourene H, Benhattar J (2007) Loss of Smad4 expression predicts liver metastasis in human colorectal cancer. Oncol Rep 17(5): 1095-1099.
26. Massague J (2008) TGFbeta in cancer. Cell 134(2): 215-230.
27. Miyaki M, Iijima T, Konishi M, Sakai K, Ishii A, Yasuno M, Hishima T, Koike M, Shitara N, Iwama T, Utsunomiya J, Kuroki T, Mori T (1999) Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene 18(20): 3098-3103.
28. Nicholson KM, Anderson NG (2002) The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14(5): 381-395.
29. Noda T, Nagano H, Takemasa I, Yoshioka S, Murakami M, Wada H, Kobayashi S, Marubashi S, Takeda Y, Dono K, Umeshita K, Matsuura N, Matsubara K, Doki Y, Mori M, Monden M (2009) Activation of Wnt/betacatenin signalling pathway induces chemoresistance to interferon-Alpha// 5-fluorouracil combination therapy for hepatocellular carcinoma. Br J Cancer 100(10): 1647-1658.
30. Papageorgis P, Cheng K, Ozturk S, Gong Y, Lambert AW, Abdolmaleky HM, Zhou JR, Thiagalingam S (2011) Smad4 inactivation promotes malignancy and drug resistance of colon cancer. Cancer Res 71(3): 998-1008.
31. Roth AD, Delorenzi M, Tejpar S, Yan P, Klingbiel D, Fiocca R, d'Ario G, Cisar L, Labianca R, Cunningham D, Nordlinger B, Bosman F, Van Cutsem E (2012) Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer. J Natl Cancer Inst 104(21): 1635-1646.
32. Samuel S, Fan F, Dang LH, Xia L, Gaur P, Ellis LM (2011) Intracrine vascular endothelial growth factor signaling in survival and chemoresistance of human colorectal cancer cells. Oncogene 30(10): 1205-1212.
33. Shin JY, Kim JO, Lee SK, Chae HS, Kang JH (2010) LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells. BMC Cancer 10: 425.
34. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1): 10-29.
35. Taiyoh H, Kubota T, Fujiwara H, Matsumura A, Murayama Y, Okamoto K, Ichikawa D, Ochiai T, Nakamura T, Matsumoto K, Otsuji E (2011) NK4 gene expression enhances 5-fluorouracil-induced apoptosis of murine colon cancer cells. Anticancer Res 31(6): 2217-2224.
36. Wagner M, Roh V, Strehlen M, Laemmle A, Stroka D, Egger B, Trochsler M, Hunt KK, Candinas D, Vorburger SA (2009) Effective treatment of advanced colorectal cancer by rapamycin and 5-FU/oxaliplatin monitored by TIMP-1. J Gastrointest Surg 13(10): 1781-1790.
37. You F, Aoki K, Ito Y, Nakashima S (2009) AKT plays a pivotal role in the acquisition of resistance to 5-fluorouracil in human squamous carcinoma cells. Mol Med Report 2(4): 609-613.
38. Zhang B, Halder SK, Kashikar ND, Cho YJ, Datta A, Gorden DL, Datta PK (2010) Antimetastatic role of Smad4 signaling in colorectal cancer. Gastroenterology 138(3): 969-980 e961-963.
39. Zhang B, Halder SK, Zhang S, Datta PK (2009) Targeting transforming growth factor-beta signaling in liver metastasis of colon cancer. Cancer Lett 277(1): 114-120.
40. Zheng G, Xiong Y, Yi S, Zhang W, Peng B, Zhang Q, He Z (2012) 14-3-3sigma regulation by p53 mediates a chemotherapy response to 5-fluorouracil in MCF-7 breast cancer cells via Akt inactivation. FEBS Lett 586(2): 163-168.